Sorafenib News and Research

RSS
Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).
Grapefruit juice boosts efficacy of drug rapamycin

Grapefruit juice boosts efficacy of drug rapamycin

Sorafenib may help patients suffering from advanced portal hypertension

Sorafenib may help patients suffering from advanced portal hypertension

FDA approves Afinitor oral tablets (everolimus) for advanced form of kidney cancer

FDA approves Afinitor oral tablets (everolimus) for advanced form of kidney cancer

Trial of new combination treatment targeting hormone receptor-positive locally advanced breast cancer

Trial of new combination treatment targeting hormone receptor-positive locally advanced breast cancer

New trial targets kidney cancer drug sorafenib in bladder cancer

New trial targets kidney cancer drug sorafenib in bladder cancer

UK kidney cancer patients face toxic, out-dated treatments with little hope of change

UK kidney cancer patients face toxic, out-dated treatments with little hope of change

ZymoGenetics presents interim Interleukin 21 phase 2 results in renal cell cancer

ZymoGenetics presents interim Interleukin 21 phase 2 results in renal cell cancer

Gene study sheds new light on lung cancer

Gene study sheds new light on lung cancer

Antisoma commences phase II trial of AS1411 in metastatic renal cell carcinoma

Antisoma commences phase II trial of AS1411 in metastatic renal cell carcinoma

Protherics announces start of Prolarix phase 2 study in liver cancer

Protherics announces start of Prolarix phase 2 study in liver cancer

Sorafenib extends life of advanced liver cancer patients

Sorafenib extends life of advanced liver cancer patients

Nanoparticles trigger built-in cell-death signal to overcome drug resistance

Nanoparticles trigger built-in cell-death signal to overcome drug resistance

Cancer drug shows promise as treatment for pulmonary hypertension

Cancer drug shows promise as treatment for pulmonary hypertension

Combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer

Combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer

Treatment with sunitinib slows tumor growth and spread of liver cancer

Treatment with sunitinib slows tumor growth and spread of liver cancer

Targeted therapy combo overcomes treatment resistance in liver cancer

Targeted therapy combo overcomes treatment resistance in liver cancer

Targeted therapies overcome treatment resistance in liver cancer cell lines

Targeted therapies overcome treatment resistance in liver cancer cell lines

Benefits of some cancer drugs exaggerated because trials were stopped early

Benefits of some cancer drugs exaggerated because trials were stopped early

Research to lead to brain tumor therapies

Research to lead to brain tumor therapies

Kidney cancer drug attacks a major type of acute myeloid leukemia

Kidney cancer drug attacks a major type of acute myeloid leukemia